Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Boswellia serrata is an Ayurvedic herb containing boswellic acids that inhibit 5-lipoxygenase enzyme to reduce inflammatory pathways. The resin extract has been traditionally used for joint health and inflammatory conditions.
Origin & History
Boswellia serrata, known as Indian frankincense, is a tree native to India belonging to the Burseraceae family. The oleogum resin (olibanum) is harvested by making incisions in the bark, yielding a resin containing acid resin (6%), gum (30-36%), and essential oils that can be extracted via steam distillation.
Research Narrative (Provisional)
The research dossier indicates that search results lack specific details on human clinical trials, RCTs, or meta-analyses for Boswellia serrata, including no PubMed PMIDs, study designs, or outcome data. While general mentions exist of oral therapeutic use, no trial data is provided in the available research.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Boswellia serrata resin and extracts are not consumed as a conventional food source, so macronutrient profiling is not the primary framework; however, key compositional data is established. The resin comprises approximately 5–10% essential oils (monoterpenes and diterpenes including α-thujene, α-pinene, and limonene), 60–70% resin acids (triterpenoids), and 20–30% polysaccharides (arabinose, galactose-based gums). The primary bioactive compounds are pentacyclic triterpenic boswellic acids, constituting roughly 25–40% of the dry resin extract: β-boswellic acid (~15–20% of total boswellic acid fraction), acetyl-β-boswellic acid, 11-keto-β-boswellic acid (KBA), and acetyl-11-keto-β-boswellic acid (AKBA, approximately 1–5% in raw resin, enriched to 10–30% in standardized extracts such as Shallaki or 5-Loxin). AKBA is considered the most potent 5-lipoxygenase inhibitor with an IC50 in the low micromolar range. Standardized commercial extracts (e.g., 65% total boswellic acids by HPLC) are the most studied forms. Bioavailability of boswellic acids is notably limited by poor aqueous solubility; oral bioavailability is enhanced when taken with a high-fat meal (lipid co-administration increases Cmax by approximately 2–3 fold). Phospholipid complexes (e.g., Phytosome formulations) further improve absorption. Mineral and vitamin content in resin extracts is negligible and not nutritionally significant. Protein content is minimal (<1%). Dietary fiber equivalents from polysaccharide gums are present but not relevant at supplemental doses (typical clinical doses: 300–500 mg standardized extract, 2–3 times daily).
Reported Mechanism (Provisional)
Boswellic acids, particularly AKBA (3-O-acetyl-11-keto-β-boswellic acid), selectively inhibit 5-lipoxygenase enzyme, blocking leukotriene synthesis. This interruption of the arachidonic acid cascade reduces pro-inflammatory mediators like LTB4 and 5-HETE. The compounds also modulate nuclear factor-kappa B (NF-κB) signaling pathways.
Clinical Narrative (Provisional)
Current clinical evidence for Boswellia serrata remains limited despite established anti-inflammatory mechanisms. While 5-lipoxygenase inhibition by boswellic acids has been demonstrated in laboratory studies, comprehensive human trials with standardized dosing protocols are lacking. Traditional use data supports oral administration of standardized extracts, but quantified clinical outcomes and optimal dosing ranges require further research. Topical formulations exist but clinical efficacy data is not well-documented.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.